Abstract
AbstractManufacturing CAR (chimeric antigen receptor)-T cell with viral vector is expensive and time-consuming. Besides, during viral transduction, the genes encoding CARs are randomly integrated into the genome, which could cause oncogenesis or produce devastating CAR-tumor cells. Here, using virus-free and non-transgenic minicircle DNA (mcDNA) vector, we enable rapid generation of CD19 CAR-T cells within two days. Further, we demonstrate in vitro and in xenograft models that the anti-tumor effects of CD19 CAR-T cells produced by mcDNA are as effective as those produced by viral vectors. Finally, we show that our manufacturing process can avoid the production of fatal CAR-tumor cells. Taken together, we provide a fast, effective, and therapeutically safe method to generate CD19 CAR-T cells for treating leukemia.
Publisher
Cold Spring Harbor Laboratory
Reference29 articles.
1. Recent advances and discoveries in the mechanisms and functions of CAR T cells;Nature Reviews Cancer,2021
2. CD28. OX40 co-stimulatory combination is associated with long in vivo persistence and high activity of CAR. CD30 T cells;haematologica,2021
3. A comparison of chimeric antigen receptors containing CD28 versus 4-1BB costimulatory domains;Nature Reviews Clinical Oncology,2021
4. The CD28-transmembrane domain mediates chimeric antigen receptor heterodimerization with CD28;Frontiers in immunology,2021
5. CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia;Blood, The Journal of the American Society of Hematology,2015